National Cancer Institute (NCI): Carcinoma, Non-Small-Cell Lung trials

The registry lists 155 Carcinoma, Non-Small-Cell Lung studies with National Cancer Institute (NCI) as lead sponsor. 12 are open to participants now and 61 have results posted.

Early Phase 1 1Phase 1 57Phase 2 82Phase 3 21No phase 13(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialRecruitingNCT07388524Phase 3
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT07012031Phase 1/2
• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingNCT06498635Phase 3
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingNCT04267848Phase 3
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingNCT03191149Phase 2
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT02682667
• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruitingNCT02146170
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingNCT02133196Phase 2
• Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant ChemotherapyNot yet recruitingNCT01595074
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingNCT04250545Phase 1Results posted
• Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung CancerActive, not recruitingNCT04214262Phase 3Results posted
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04027946Phase 2Results posted
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03831932Phase 1/2Results posted
• Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingNCT03600701Phase 2Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results posted
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingNCT02888743Phase 2Results posted
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02642042Phase 2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsActive, not recruitingNCT02589522Phase 1Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
• Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT01935947Phase 2Results posted
• Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerCompletedNCT01866410Phase 2Results posted
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerTerminatedNCT01822496Phase 2Results posted
• Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT01708954Phase 2Results posted
• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT01642251Phase 1/2Results posted
• Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT01413750Phase 2Results posted
• Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung CancerTerminatedNCT01342770Phase 2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyCompletedNCT01294306Phase 2Results posted
• Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung CancerCompletedNCT01281124Phase 2Results posted
• Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...CompletedNCT01229150Phase 2Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By SurgeryTerminatedNCT01207726Phase 2Results posted
• RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyTerminatedNCT01193868Phase 2Results posted
• A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)CompletedNCT01100931Phase 1/2Results posted
• Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00986674Phase 2Results posted
• Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerTerminatedNCT00976677Phase 2Results posted
• A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLCCompletedNCT00963807Phase 2Results posted
• Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT00955305Phase 2Results posted
• A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung CancerTerminatedNCT00924209Phase 2Results posted
• Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung CancerTerminatedNCT00923949Phase 2Results posted
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2Results posted
• Sirolimus and Pemetrexed to Treat Non-Small Cell Lung CancerTerminatedNCT00923273Phase 1/2Results posted
• Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00778167Phase 1/2Results posted
• Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00738881Phase 3Results posted
• Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00698815Phase 2Results posted
• Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination ChemotherapyCompletedNCT00693992Phase 3Results posted
• AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyCompletedNCT00638937Phase 2Results posted
• Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00481078Phase 2Results posted
• Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00459342Phase 2Results posted
• AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung CancerCompletedNCT00410904Phase 2Results posted
• E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00400829Phase 2Results posted
• Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung CancerCompletedNCT00387465Phase 1/2Results posted
• S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00368992Phase 2Results posted
• Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerCompletedNCT00362882Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryCompletedNCT00324805Phase 3Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00138203Phase 2Results posted
• Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerCompletedNCT00118144Phase 2Results posted
• BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung CancerCompletedNCT00098254Phase 2Results posted
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerTerminatedNCT00096265Phase 3Results posted
• Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerCompletedNCT00093756Phase 1/2Results posted
• Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryCompletedNCT00049543Phase 3Results posted
• Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung CancerTerminatedNCT00004859Phase 3Results posted
• Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung CancerCompletedNCT00003869Phase 3Results posted
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesWithdrawnNCT06982222Phase 1
• Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06732401Phase 3
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT06694454Phase 1/2
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
• Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
• Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeActive, not recruitingNCT04929041Phase 2/3
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02595944Phase 3
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1
• Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1
• Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
• EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung CancerCompletedNCT02154399Phase 2
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryTerminatedNCT01912625Phase 1
• Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryTerminatedNCT01886573Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• 18F FLT Imaging Studies of Treatment Response for Lung Cancer and ThymomaWithdrawnNCT01610544Phase 2
• -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedNCT01441128Phase 1
• Amatuximab for High Mesothelin CancersTerminatedNCT01413451Early Phase 1
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center ProgramsCompletedNCT01346280